GemVax is a biopharmaceutical company focused on developing innovative vaccine therapies and antibody drugs for the prevention and treatment of cancer.

History

GemVax was founded in 1995 with its headquarters located in South Korea. Since its inception, the company has conducted research in the fields of oncology, immunology, and vaccine development. The company has successfully developed two therapeutic vaccines for the prevention and treatment of cancer and has established strategic collaborations with leading pharmaceutical companies.

Mission

The mission of GemVax is to develop innovative, efficient and effective therapeutic vaccines and antibody drugs that have the potential to make a meaningful difference to patients’ lives.

Vision

GemVax’s vision is to be a world-leading biopharmaceutical company, delivering innovative, effective and safe treatments to patients and healthcare providers.

Key Team

Kyung-Hee Kim (Vice President and Director)

Jae-Kwon Kim (Director)

Recognition and Awards

GemVax was the recipient of the 2020 Scientific American Excellence Award. The award recognizes significant advances in the fields of medicine, diagnostics and therapies that have emerged in the last year.

References

https://in.investing.com/equities/gemvax-kael-co-ltd

https://finance.yahoo.com/quote/082270.KQ/profile?p=082270.KQ

https://www.crunchbase.com/organization/gemvax

www.gemvaxtech.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Leadership team

Young-Bae Baek (Director)

Ki-Woong Kim (Director)

Sang-Jae Kim (CEO & Representative Director)

Products/ Services

Semiconductor

Number of Employees

100 - 500

Headquarters

Daejeon, Taejon-jikhalsi, South Korea

Established

1980

Revenue

5M - 20M

Traded as

KOSDAQ:041590

URL

www.gemvaxtech.com

Last updated: Tue Feb 25 2025

We value your privacy

GemVax

Table of content

Summary